RTMP COPY

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 31/415, 9/20, 9/00 — A1

(11) International Publication Number: WO 96/15785

(43) International Publication Date: 30 May 1996 (30.05.96)

(21) International Application Number: PCT/EP95/04550

(22) International Filing Date: 20 November 1995 (20.11.95)

(30) Priority Data:
9423511.6 22 November 1994 (22.11.94) GB

(71) Applicant *(for all designated States except US)*: GLAXO WELLCOME INC. [CA/CA]; 7333 Mississauga Road North, Mississauga, Ontario L5N 6L4 (CA).

(72) Inventor; and

(75) Inventor/Applicant *(for US only)*: WINTERBORN, Ian, Keith [GB/GB]; Glaxo Research and Development Limited, Park Road, Ware, Hertfordshire SG12 0DP (GB).

(74) Agent: DAWSON, Hugh, B.; Glaxo Wellcome plc, Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).

(81) Designated States: AL, AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, US, UZ, VN, European patent (AT, CH, DE, DK, ES, GR, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, LS, MW, SD, SZ, UG).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: FREEZE-DRIED ONDANSETRON COMPOSITIONS

(57) Abstract

The invention relates to a freeze-dried dosage form for oral administration capable of being rapidly disintegrated in the mouth comprising ondansetron in the form of its free base or a pharmaceutically acceptable solvate thereof and one or more pharmaceutically acceptable excipients. Methods for the manufacture of such compositions and for their use in the treatment of conditions mediated through the action of 5-hydroxytryptamine (5HT) at $5HT_3$ receptors are also described.